FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Is There a Retatrutide Pill? Why Reta Stays an Injection in 2026

Stainless-steel tablet press on a white bench in a bright lab, with a tray of plain white tablets and one small vial of white freeze-dried powder in front of it

Two weight-loss pills arrived within four months. Novo Nordisk’s Wegovy pill was approved in December 2025, then Lilly’s Foundayo on April 1, 2026, and the obvious next question about retatrutide, Lilly’s triple agonist, was whether it would come as a tablet too.

It doesn’t. Retatrutide has 33 registered studies behind it since 2019, and every one of them gives the drug by injection under the skin. Foundayo, the pill most often taken for it, is a different molecule that works on one receptor instead of three.

For laboratory research, Simms Research sells Retatrutide (GLP-3) as an injectable, four sizes of freeze-dried powder whose batch certificate is posted in full.

Is there a retatrutide pill?

No. Lilly has no retatrutide pill, capsule or drop, approved or in testing. Retatrutide itself is not approved in any form: Lilly plans to file the weekly injection with the FDA in the first quarter of 2027, and the review window that follows is mapped out in When Will Retatrutide Be FDA Approved?

The trial record leaves no room for an oral version. The first study opened in March 2019 with a single shot in healthy volunteers, and all 33 on record give retatrutide under the skin. The handful that list an oral drug use it for something else: volunteers swallow a birth control pill, warfarin or metoprolol alongside their injections, so Lilly can see whether retatrutide changes how those tablets are absorbed.

Lilly’s delivery work has gone into the injection. A study run from August 2023 to February 2024 compared retatrutide given from two different injection devices, and another measured how much reaches the blood from the thigh and upper arm against the belly, with one group dosed straight into a vein. That is groundwork for an injection device, not a tablet.

Is retatrutide a pill or an injection?

An injection, once a week, into the fat under the skin of the belly, thigh or upper arm. It is a peptide, and every result it is known for, from the Phase 2 trial to the 28.3% average at 80 weeks in TRIUMPH-1, came from that weekly shot. The molecule and its trials are covered in what retatrutide is.

Why retatrutide is an injection, not a pill

Because the gut digests peptides. Retatrutide is a chain of 39 amino acids, and swallowed, it meets the same machinery that breaks down the protein in a meal.

The stomach goes first, with acid and pepsin cutting into the chain. Whatever survives reaches the small intestine, where trypsin, chymotrypsin and a run of other enzymes exist to reduce proteins to single amino acids. A molecule that gets through intact still has to cross the gut wall, a lining that lets small molecules pass and holds large ones back. Most tablet drugs weigh under 500 daltons. Retatrutide weighs 4,731.

Its built-in protections face the blood, not the gut. The unusual amino acids in the chain fend off the enzyme that clears natural GLP-1 within minutes, and the fatty tail rides on albumin for days. Neither was designed to outlast pepsin.

Under the skin, the same molecule does exactly what it was built for. It seeps into the blood over one to three days and takes about six to fall by half, so a single shot covers the week, a curve traced dose by dose in the retatrutide half-life guide. A tablet delivers its dose in one pass through the gut, and every GLP-1 tablet on the market is taken daily.

Row of clear glass diffusion chambers clamped over a steel warm-water bath with thin tubing, beside a closed grey notebook on a white lab bench

How the GLP-1 pills got past the gut

Two ways. Novo Nordisk shielded a peptide and accepted heavy losses; Lilly dropped the peptide altogether.

Oral semaglutide: the same peptide with a shield

The Wegovy pill is semaglutide, the peptide in Ozempic and Wegovy, pressed into a tablet with an absorption enhancer called SNAC. It buffers the acid around the tablet and helps the peptide through the stomach lining, and even then only about 0.4% to 1% of each dose reaches the blood. So the tablet goes down on an empty stomach with no more than half a cup of water, and nothing else for 30 minutes. Rybelsus brought the method to type 2 diabetes in 2019; the 25mg Wegovy pill was approved for weight loss on December 22, 2025.

The losses show in the dose. The Wegovy injection tops out at 2.4mg a week. The pill is 25mg a day, 175mg a week, about 73 times as much semaglutide for a similar result: 13.6% average weight loss at 64 weeks, against 2.2% on placebo (Wharton, New England Journal of Medicine, 2025).

Put retatrutide through the same ratio and its 12mg weekly top dose becomes roughly 875mg by mouth, more than fourteen 60mg vials every week.

Orforglipron: no peptide at all

Lilly went the other way. Orforglipron, discovered by Chugai and licensed by Lilly in 2018, is a small molecule designed to switch on the GLP-1 receptor, with a molecular weight of 883 against retatrutide’s 4,731. There is no peptide chain for the stomach to cut, it absorbs like an ordinary tablet, and it comes with no food or water rules.

The trade is reach. Orforglipron works on one receptor, GLP-1, and no approved pill of either kind touches the GIP or glucagon receptors that set retatrutide apart.

Is Foundayo the retatrutide pill?

No. Foundayo is orforglipron, a once-daily GLP-1 tablet. Retatrutide is a once-weekly injection that also works on the GIP and glucagon receptors. Both come from Lilly, and both made headlines in 2026, which is where the mix-up starts.

The FDA approved Foundayo for chronic weight management on April 1, 2026, 50 days after Lilly filed, under one of its national priority vouchers. It comes in six strengths from 0.8mg to 17.2mg, taken at any time of day, and Lilly’s own pharmacy began shipping it on April 6, with self-pay starting at $149 a month on the lowest strength.

Its weight numbers sit well below retatrutide’s. In ATTAIN-1, 3,127 adults without diabetes took orforglipron or placebo for 72 weeks, and those who stayed on the top trial dose lost 12.4% against 0.9% on placebo. On the same measure, retatrutide’s top dose reached 28.3% at 80 weeks. The trials ran separately, in different people over different lengths, so the gap is a guide rather than a head-to-head result.

Retatrutide pill vs injection

Every pill on the market works on GLP-1 alone, and the strongest of them lands about where the weekly Wegovy shot does. Retatrutide’s three receptors are the step beyond that, and for now they come only as an injection:

TreatmentFormHow oftenReceptorsAverage weight loss, top dose
RetatrutideInjectionOnce a weekGLP-1, GIP, glucagon28.3% at 80 weeks
Wegovy (semaglutide)InjectionOnce a weekGLP-116.9% at 68 weeks
Wegovy pill (semaglutide)TabletDaily, empty stomachGLP-116.6% at 64 weeks
Foundayo (orforglipron)TabletDaily, any timeGLP-112.4% at 72 weeks
Oral retatrutide sold onlineCapsule, drop or stripVaries by sellerSame three, if absorbedNo human data

Each figure is the average among people who kept taking the drug, from its own placebo-controlled trial. What a tablet buys is the absence of a needle. What it costs is a daily dose, and for the Wegovy pill a fasting routine every morning, where retatrutide asks for one injection a week.

Manual capsule-filling plate holding rows of empty clear capsules on a pale blue bench, with loose capsules and a glass dish of white powder beside it

Oral retatrutide drops, capsules and tablets sold online

They put the injectable peptide, or say they do, into a form no study has tested. None comes with absorption data: no blood levels after a dose, no comparison against an injection of the same amount.

Capsules, tablets, drops and dissolving strips are all sold with retatrutide on the label. The numbers used to sell them, 28.3% at 80 weeks among them, come from doses injected under the skin, and they don’t transfer to a capsule. Oral semaglutide needed a purpose-built enhancer and dozens of times the injected amount to match its own shot, and nothing shows a retatrutide capsule clearing either bar.

Under the tongue changes the route more than the result. The lining of the mouth takes up small molecules readily, but a 39-amino-acid chain carrying a fatty tail is far beyond what it absorbs on its own, and no one has measured retatrutide crossing it.

Supplement drops sold with GLP in the name are a separate category again. The GLP-1 drops and capsules on supplement shelves list plant extracts such as berberine, cinnamon and chromium, not a peptide.

Will there be a retatrutide pill?

Not on anything Lilly has published. Its filing in early 2027 is for the weekly injection, and its pill for weight is orforglipron.

The spending says the same. Lilly broke ground in Pennsylvania’s Lehigh Valley on November 12, 2026 for a $3.5 billion plant for injectable medicines and the devices that deliver them, and retatrutide is one of the drugs it is being built to make.

Other companies are chasing the idea with molecules of their own. Viking Therapeutics took a once-daily VK2735 tablet, which works on GLP-1 and GIP, into Phase 3 in October 2026, after people on it lost up to 12.2% on average in 13 weeks. Protagonist Therapeutics named PN-477, an oral peptide aimed at all three of retatrutide’s receptors, as its candidate in June 2025, with first human studies planned for 2026.

A pill that does what retatrutide does would be a new drug with its own trials, years behind the injection. For anyone working with retatrutide now, the form is settled: a vial, mixed with water and measured once a week.

Laboratory freeze-dryer with its glass door open and three steel shelves of small plain vials holding white freeze-dried powder, in a bright lab

How retatrutide is sold for research

As freeze-dried powder sealed in glass, the stable form a peptide keeps until it is mixed with bacteriostatic water. That makes it an injectable from the start, the same route as every trial.

Simms Research carries Retatrutide (GLP-3) in four vial sizes, read at their regular prices on November 16, 2026: $84 for 10mg and $129 for 20mg, then 30mg for $159 and 60mg for $259. Their latest batch was tested on July 16, 2026 by an independent ISO-certified lab: 99.611% pure by RP-HPLC, identity confirmed by LC-MS, and three vials sold as 10mg measured 10.68mg net. Endotoxins passed, heavy metals came back negative and the microbial test showed no growth; the certificate is posted under retatrutide lab results.

Water amounts for each size are in How to Reconstitute Retatrutide, the weekly steps sit in the retatrutide dosage chart, and the retatrutide calculator turns any dose into units on the syringe. A month at each step is priced out in retatrutide cost per month.

If the appeal of a pill is skipping the syringe, a reusable pen is the nearer answer. The Peptide Injection Pen takes a mixed vial in a 3mL cartridge and dials each dose in single units, and the retatrutide pen guide walks through loading it from every vial size.

Frequently asked questions

Can you take retatrutide orally?

Not with any evidence behind it. Swallowed, it is digested like the protein in food, no study has ever given it by mouth, and every figure from its trials comes from an injection.

Is there a retatrutide nasal spray?

No. Nasal sprays suit short peptides such as Semax and Selank, seven amino acids each. Retatrutide has 39 and a fatty tail, and no trial has given it through the nose.

How much does a retatrutide pill cost?

There is no retatrutide pill to price. Foundayo, Lilly’s GLP-1 tablet, starts at $149 a month self-pay. Research retatrutide is priced by the vial, from $84 for 10mg.

Is Simms Research legit?

Yes, and each point can be checked. Simms Research ships from Florida to all 50 states, sending orders placed before 5PM Eastern out the same day. The purity, net content and contaminant results for their retatrutide batch are posted before anyone pays, and their Free Delivery Guarantee covers a parcel that goes missing, is stolen after a delivery scan or turns up damaged. The support line, 855-592-8507, is open Monday to Friday, 9AM to 5PM Eastern, and support@simmsresearch.com replies to most messages within one business day.

Does this page have a retatrutide coupon?

None. Nothing here is sponsored, no link earns a commission, and the vial prices quoted are the regular ones.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results